NO20072092L - Sulfonamidforbindelser - Google Patents
SulfonamidforbindelserInfo
- Publication number
- NO20072092L NO20072092L NO20072092A NO20072092A NO20072092L NO 20072092 L NO20072092 L NO 20072092L NO 20072092 A NO20072092 A NO 20072092A NO 20072092 A NO20072092 A NO 20072092A NO 20072092 L NO20072092 L NO 20072092L
- Authority
- NO
- Norway
- Prior art keywords
- cck2
- compounds
- sulfonamide
- cck1
- sulfionamide
- Prior art date
Links
- 229940124530 sulfonamide Drugs 0.000 title 1
- 150000003456 sulfonamides Chemical class 0.000 title 1
- ARLKVQYMFRECLV-JSGCOSHPSA-N (2s)-2-[[(2s)-2-amino-3-(1h-indol-3-yl)propanoyl]amino]-4-methylsulfanylbutanamide Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CCSC)C(N)=O)=CNC2=C1 ARLKVQYMFRECLV-JSGCOSHPSA-N 0.000 abstract 2
- 102100021942 C-C motif chemokine 28 Human genes 0.000 abstract 2
- 108091005932 CCKBR Proteins 0.000 abstract 2
- 101000897477 Homo sapiens C-C motif chemokine 28 Proteins 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000009977 dual effect Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/14—Thiadiazoles; Hydrogenated thiadiazoles condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
- C07D419/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D419/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Addiction (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Nutrition Science (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Materials For Medical Uses (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61272004P | 2004-09-24 | 2004-09-24 | |
| PCT/US2005/033692 WO2006036670A1 (en) | 2004-09-24 | 2005-09-19 | Sulfonamide compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20072092L true NO20072092L (no) | 2007-06-22 |
Family
ID=35781432
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20072092A NO20072092L (no) | 2004-09-24 | 2007-04-23 | Sulfonamidforbindelser |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US7297816B2 (es) |
| EP (1) | EP1797083A1 (es) |
| JP (1) | JP2008514608A (es) |
| KR (1) | KR20070057252A (es) |
| CN (1) | CN101061116A (es) |
| AR (1) | AR050953A1 (es) |
| AU (1) | AU2005289887A1 (es) |
| BR (1) | BRPI0516027A (es) |
| CA (1) | CA2581426A1 (es) |
| CR (1) | CR9080A (es) |
| EA (1) | EA200700717A1 (es) |
| EC (1) | ECSP077360A (es) |
| IL (1) | IL182149A0 (es) |
| MX (1) | MX2007003623A (es) |
| NO (1) | NO20072092L (es) |
| PE (1) | PE20060823A1 (es) |
| WO (1) | WO2006036670A1 (es) |
| ZA (1) | ZA200702452B (es) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA84025C2 (en) * | 2003-08-08 | 2008-09-10 | Янссен Фармацевтика Н.В. | Normal;heading 1;heading 2;2-(QUINOXALIN-5-YLSULFONYLAMINO)-BENZAMIDE COMPOUNDS AS CCK2 MODULATORS |
| JP2008514608A (ja) | 2004-09-24 | 2008-05-08 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | スルホンアミド化合物 |
| UA103319C2 (en) | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
| TW201124406A (en) | 2009-10-07 | 2011-07-16 | Karobio Ab | Novel estrogen receptor ligands |
| MX337575B (es) | 2009-10-09 | 2016-03-10 | Zafgen Corp | Compuestos de sulfona y métodos para lafabricación y uso de éstos. |
| AU2011281037B2 (en) | 2010-07-22 | 2014-11-27 | Zafgen, Inc. | Tricyclic compounds and methods of making and using same |
| WO2012103333A1 (en) | 2011-01-26 | 2012-08-02 | Zafgen Corporation | Tetrazole compounds and methods of making and using same |
| SG194812A1 (en) | 2011-05-06 | 2013-12-30 | Zafgen Inc | Partially saturated tricyclic compounds and methods of making and using same |
| CN103748094B (zh) | 2011-05-06 | 2016-06-29 | 扎夫根股份有限公司 | 三环磺酰胺化合物及其制备和使用方法 |
| US9242997B2 (en) | 2011-05-06 | 2016-01-26 | Zafgen, Inc. | Tricyclic pyrazole sulphonamide compunds and methods of making and using same |
| WO2013056015A1 (en) | 2011-10-14 | 2013-04-18 | Incyte Corporation | Isoindolinone and pyrrolopyridinone derivatives as akt inhibitors |
| WO2013109735A1 (en) | 2012-01-18 | 2013-07-25 | Zafgen, Inc. | Tricyclic sulfone compounds and methods of making and using same |
| BR112014017673A8 (pt) | 2012-01-18 | 2017-07-11 | Zafgen Inc | Compostos de sulfonamida tricíclicos e métodos para fazer e usar os mesmos |
| BR112014030412A2 (pt) | 2012-06-14 | 2017-06-27 | Basf Se | método para combater ou controlar pragas, método para proteger culturas, compostos, processo para a preparação de compostos, uso de um composto, composição agrícola ou veterinária e semente. |
| MX2015005733A (es) | 2012-11-05 | 2016-02-10 | Zafgen Inc | Compuestos triciclicos para usarse en el tratamiento y/o control de obesidad. |
| BR112015010196A2 (pt) | 2012-11-05 | 2017-07-11 | Zafgen Inc | métodos de tratar doença do fígado |
| KR20150079952A (ko) | 2012-11-05 | 2015-07-08 | 자프겐 인크. | 트리시클릭 화합물 및 그의 제조 및 사용 방법 |
| CN103183623A (zh) * | 2013-03-12 | 2013-07-03 | 中国医学科学院医药生物技术研究所 | 一组苯磺酰胺基苯甲酰胺类衍生物及制备和应用 |
| WO2015077572A1 (en) | 2013-11-22 | 2015-05-28 | CL BioSciences LLC | Gastrin antagonists (eg yf476, netazepide) for treatment and prevention of osteoporosis |
| WO2015097121A1 (en) * | 2013-12-23 | 2015-07-02 | Norgine B.V. | Compounds useful as ccr9 modulators |
| WO2015117147A1 (en) | 2014-02-03 | 2015-08-06 | Quadriga Biosciences, Inc. | Beta-substituted beta-amino acids and analogs as chemotherapeutic agents |
| BR112016017993A2 (pt) | 2014-02-03 | 2017-08-08 | Quadriga Biosciences Inc | Gama-aminoácidos beta-substituídos e análogos como agentes quimioterapêuticos |
| KR20180035894A (ko) | 2015-08-03 | 2018-04-06 | 콰드리가 바이오사이언시스 인코포레이티드 | 화학치료제로서의 베타-치환된 베타-아미노산 및 유사체 및 이들의 용도 |
| CN116854620B (zh) * | 2023-03-10 | 2024-10-15 | 徐州医科大学 | 一种pcbp1基因编码蛋白异常相分离抑制剂 |
| CN117776984B (zh) * | 2023-12-11 | 2026-04-03 | 浙江博崤生物制药有限公司 | 一种立他司特中间体的制备方法 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT77219B (fr) | 1982-08-24 | 1986-02-04 | May & Baker Ltd | Procede de preparation des derives de la benzamide |
| KR0143565B1 (ko) * | 1988-06-13 | 1998-07-15 | 사노 가즈오 | 피발산의 p-치환된 페닐 에스테르 유도체, 그의 제조 방법 및 이를 포함하는 조성물. |
| CA2057324A1 (en) * | 1990-12-18 | 1992-06-19 | Lora Louise Fitch | Benzamide and sulfonamide hypoglycemic agents |
| IL101514A (en) * | 1991-04-10 | 1996-01-31 | Merck & Co Inc | Benzodiazepinone derivatives and cholecystokinin antagonist pharmaceutical compositions containing them |
| FR2703995B1 (fr) | 1993-04-16 | 1995-07-21 | Sanofi Elf | 5-acylamino 1,2,4-thiadiazoles, leur preparation et compositions pharmaceutiques en contenant. |
| US20020168761A1 (en) * | 2000-01-24 | 2002-11-14 | Gour Barbara J. | Peptidomimetic modulators of cell adhesion |
| PT945445E (pt) | 1996-12-10 | 2004-01-30 | Zeria Pharm Co Ltd | Derivados de 1,5-benzodiazepina |
| WO2000078145A1 (en) | 1999-06-24 | 2000-12-28 | Smithkline Beecham Corporation | Macrophage scavenger receptor antagonists |
| DE10121002A1 (de) * | 2001-04-28 | 2002-11-14 | Aventis Pharma Gmbh | Verwendung von Anthranilsäureamiden als Medikament zur Behandlung von Arrhythmien sowie sie enthaltende pharmazeutische Zubereitungen |
| DE10121003A1 (de) * | 2001-04-28 | 2002-12-19 | Aventis Pharma Gmbh | Anthranilsäureamide, Verfahren zur Herstellung, ihrer Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen |
| DE10128331A1 (de) * | 2001-06-12 | 2002-12-19 | Aventis Pharma Gmbh | Anthranilsäureamide mit Heteroarylsulfonyl-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen |
| AR039241A1 (es) | 2002-04-04 | 2005-02-16 | Biogen Inc | Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos |
| ITTO20020674A1 (it) | 2002-07-26 | 2004-01-26 | Rotta Research Lab | Derivati antranilici ad attivita' anticolecistochininica (anti-cck-1), procedimento per la loro preparazione e loro uso farmaceutico |
| JP2006528241A (ja) | 2003-03-28 | 2006-12-14 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ベンゾ［１，２，５］チアジアゾール化合物 |
| GB0312368D0 (en) | 2003-05-30 | 2003-07-02 | Univ Aston | Novel ureido- and amido-pyrazolone derivatives |
| GB0312365D0 (en) | 2003-05-30 | 2003-07-02 | Univ Aston | Novel 3-substituted-1, 4-benzodiazepines |
| GB0312360D0 (en) | 2003-05-30 | 2003-07-02 | Univ Aston | Novel 4-amino-2(5H)-furanones |
| WO2005007107A2 (en) | 2003-07-11 | 2005-01-27 | University Of Massachusetts | Histamine and cck2/gastrin receptor blockade in the treatment of acid-peptic disease and cancer |
| UA84025C2 (en) | 2003-08-08 | 2008-09-10 | Янссен Фармацевтика Н.В. | Normal;heading 1;heading 2;2-(QUINOXALIN-5-YLSULFONYLAMINO)-BENZAMIDE COMPOUNDS AS CCK2 MODULATORS |
| JP2008514608A (ja) | 2004-09-24 | 2008-05-08 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | スルホンアミド化合物 |
-
2005
- 2005-09-19 JP JP2007533587A patent/JP2008514608A/ja not_active Withdrawn
- 2005-09-19 KR KR1020077009003A patent/KR20070057252A/ko not_active Withdrawn
- 2005-09-19 WO PCT/US2005/033692 patent/WO2006036670A1/en not_active Ceased
- 2005-09-19 CA CA002581426A patent/CA2581426A1/en not_active Abandoned
- 2005-09-19 EP EP05806708A patent/EP1797083A1/en not_active Withdrawn
- 2005-09-19 MX MX2007003623A patent/MX2007003623A/es active IP Right Grant
- 2005-09-19 BR BRPI0516027-8A patent/BRPI0516027A/pt not_active IP Right Cessation
- 2005-09-19 CN CNA200580039886XA patent/CN101061116A/zh active Pending
- 2005-09-19 EA EA200700717A patent/EA200700717A1/ru unknown
- 2005-09-19 AU AU2005289887A patent/AU2005289887A1/en not_active Abandoned
- 2005-09-19 US US11/230,249 patent/US7297816B2/en not_active Expired - Lifetime
- 2005-09-23 PE PE2005001105A patent/PE20060823A1/es not_active Application Discontinuation
- 2005-09-26 AR ARP050104015A patent/AR050953A1/es not_active Application Discontinuation
-
2007
- 2007-03-22 IL IL182149A patent/IL182149A0/en unknown
- 2007-03-23 ZA ZA200702452A patent/ZA200702452B/xx unknown
- 2007-03-29 EC EC2007007360A patent/ECSP077360A/es unknown
- 2007-04-20 CR CR9080A patent/CR9080A/es not_active Application Discontinuation
- 2007-04-23 NO NO20072092A patent/NO20072092L/no not_active Application Discontinuation
- 2007-11-20 US US11/943,520 patent/US7855292B2/en not_active Expired - Fee Related
-
2010
- 2010-07-26 US US12/843,682 patent/US20100292240A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US7297816B2 (en) | 2007-11-20 |
| ZA200702452B (en) | 2009-05-27 |
| CA2581426A1 (en) | 2006-04-06 |
| US7855292B2 (en) | 2010-12-21 |
| PE20060823A1 (es) | 2006-09-23 |
| ECSP077360A (es) | 2007-04-26 |
| US20100292240A1 (en) | 2010-11-18 |
| BRPI0516027A (pt) | 2008-08-19 |
| AU2005289887A1 (en) | 2006-04-06 |
| CN101061116A (zh) | 2007-10-24 |
| US20060069286A1 (en) | 2006-03-30 |
| JP2008514608A (ja) | 2008-05-08 |
| CR9080A (es) | 2008-09-09 |
| US20080132511A1 (en) | 2008-06-05 |
| IL182149A0 (en) | 2007-07-24 |
| MX2007003623A (es) | 2007-09-11 |
| EA200700717A1 (ru) | 2007-10-26 |
| WO2006036670A1 (en) | 2006-04-06 |
| EP1797083A1 (en) | 2007-06-20 |
| KR20070057252A (ko) | 2007-06-04 |
| AR050953A1 (es) | 2006-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20072092L (no) | Sulfonamidforbindelser | |
| NO20061122L (no) | 2-(Quinoksalin-5-ylsuflonylamino)-benzamid forbindelser som CCK2 modulatorer | |
| NO20081636L (no) | FAP - inhibitorer | |
| CY2016015I1 (el) | Αζετιδινες ως αναστολεις μεκ για τη θεραπευτικη αγωγη πολλαπλασιαστικων ασθενειων | |
| NO20081788L (no) | Cyklopropylaminer som modulatorer av histamin-H3-reseptoren | |
| CY1122522T1 (el) | Μετα αρσενικωδες νατριο για χρηση στην αγωγη του πολλαπλου μυελωματος | |
| NO20083002L (no) | Fremgangsmate for anvendelse av CD40-bindende forbindelser | |
| NO20085029L (no) | Substituerte pyridylamidforbindelser som modulatorer av histamin H3 reseptoren | |
| EA201070247A1 (ru) | Ингибиторы протеасом | |
| DK1206474T3 (da) | Sulfonylphenylpyrazolforbindelser anvendelige som cox-2-inhibitorer | |
| ATE532518T1 (de) | Dipeptidyl-peptidase-hemmer zur behandlung von diabetes | |
| NO20092658L (no) | New compounds | |
| NO20070933L (no) | Indazoler anvendbare i behandling av kardiovaskulaere sykdommer | |
| EA200701467A1 (ru) | Пирролидиновые ингибиторы иап (ингибиторов апоптоза) | |
| EA201170521A1 (ru) | Новые соединения | |
| UA85559C2 (en) | Aminobenzophenone compounds | |
| EA200802213A1 (ru) | Способы лечения заболеваний крови | |
| NO20082594L (no) | Pyrimidinylbenzotiofenforbindelser | |
| CL2007002384A1 (es) | Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de la psoriasis. | |
| EA200701396A1 (ru) | Триазолофталазины в качестве ингибиторов pde-2 | |
| EA200602129A1 (ru) | Новое применение пептидных соединений для лечения дискинезии | |
| EA201170344A1 (ru) | Азаиндольные ингибиторы iap | |
| ATE471324T1 (de) | Triazolophthalazine | |
| EA201000494A1 (ru) | Новые гидрокси-8-гетероарилфенантридины и их применение в качестве ингибиторов pde4 | |
| UA90698C2 (en) | Triazole substituted aminobenzophenone compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |